Paeoniflorin promotes intestinal stem cell-mediated epithelial regeneration and repair via PI3K-AKT-mTOR signalling in ulcerative colitis
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110247 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Yujing Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Hebei University of Chinese Medicine, China; Hebei University of Chinese Medicine, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Colitis. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Ulcerative colitis (UC) is a chronic and immune-mediated inflammatory disorder characterized by abdominal pain, diarrhoea, and haematochezia. The goal of clinical therapy for UC is mucosal healing, accomplished by regenerating and repairing the intestinal epithelium. Paeoniflorin (PF) is a natural ingredient extracted from Paeonia lactiflora that has significant anti-inflammatory and immunoregulatory efficacy. In this study, we investigated how PF could regulate the renewal and differentiation of intestinal stem cells (ISCs) to improve the regeneration and repair of the intestinal epithelium in UC. Our experimental results showed that PF significantly alleviated colitis induced by dextran sulfate sodium (DSS) and ameliorated intestinal mucosal injury by regulating the renewal and differentiation of ISCs. The mechanism by which PF regulates ISCs was confirmed to be through PI3K-AKT-mTOR signalling. In vitro, we found that PF not only improved the growth of TNF-α-induced colon organoids but also increased the expression of genes and proteins related to the differentiation and regeneration of ISCs. Furthermore, PF promoted the repair ability of lipopolysaccharide (LPS)-induced IEC-6 cells. The mechanism by which PF regulates ISCs was further confirmed and was consistent with the in vivo results. Overall, these findings demonstrate that PF accelerates epithelial regeneration and repair by promoting the renewal and differentiation of ISCs, suggesting that PF treatment may be beneficial to mucosal healing in UC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Hebei University of Chinese Medicine, China; Hebei University of Chinese Medicine, China.
- The First Affiliated Hospital of Hebei University of Chinese Medicine, China.
- Xingtai Medical College, China.
- Hebei University of Chinese Medicine, China.
- The First Affiliated Hospital of Hebei University of Chinese Medicine, China. Electronic address: 1535392045@hebcm.edu.cn.
Zitieren
APA
Ma, Y., Lang, X., Yang, Q., Han, Y., Kang, X., Long, R., Du, J., Zhao, M., Liu, L., Li, P., & Liu, J. (2023). Paeoniflorin promotes intestinal stem cell-mediated epithelial regeneration and repair via PI3K-AKT-mTOR signalling in ulcerative colitis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110247
Vancouver
Ma Y, Lang X, Yang Q, Han Y, Kang X, Long R, et al. Paeoniflorin promotes intestinal stem cell-mediated epithelial regeneration and repair via PI3K-AKT-mTOR signalling in ulcerative colitis. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110247
BibTeX
@article{Ma2023,
author = {Ma, Yujing and Lang, Xiaomeng and Yang, Qian and Han, Yan and Kang, Xin and Long, Run and Du, Jingxia and Zhao, Mengmeng and Liu, Longhui and Li, Peitong and Liu, Jianping},
title = {Paeoniflorin promotes intestinal stem cell-mediated epithelial regeneration and repair via PI3K-AKT-mTOR signalling in ulcerative colitis},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110247}
}
EUVIMED